These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31133363)

  • 41. Evaluating glioma therapies: modeling treatments and predicting outcomes.
    Kirby S; Brothers M; Irish W; Florell R; Macdonald D; Schold C; Cairncross G
    J Natl Cancer Inst; 1995 Dec; 87(24):1884-8. PubMed ID: 7494233
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Eligibility for the surgical trial in intracerebral hemorrhage II study in a population-based cohort.
    Adeoye O; Woo D; Haverbusch M; Tao H; Sekar P; Moomaw CJ; Shutter L; Kleindorfer D; Kissela B; Broderick J; Flaherty ML
    Neurocrit Care; 2008; 9(2):237-41. PubMed ID: 18183500
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
    Tong KM; Laskin J; Ho C
    Lung Cancer; 2015 Mar; 87(3):296-302. PubMed ID: 25601487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group.
    Magnuson A; Bruinooge SS; Singh H; Wilner KD; Jalal S; Lichtman SM; Kluetz PG; Lyman GH; Klepin HD; Fleury ME; Hirsch B; Melemed A; Arnaldez FI; Basu Roy U; Schenkel C; Sherwood S; Garrett-Mayer E
    Clin Cancer Res; 2021 May; 27(9):2424-2429. PubMed ID: 33563633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?
    Skaga E; Skretteberg MA; Johannesen TB; Brandal P; Vik-Mo EO; Helseth E; Langmoen IA
    Neurooncol Adv; 2021; 3(1):vdab008. PubMed ID: 33665615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of a 'Watch and Wait' Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population.
    Noonan K; Tong KM; Laskin J; Zheng YY; Melosky B; Sun S; Murray N; Ho C
    Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):505-13. PubMed ID: 26095646
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
    Osarogiagbon RU; Vega DM; Fashoyin-Aje L; Wedam S; Ison G; Atienza S; De Porre P; Biswas T; Holloway JN; Hong DS; Wempe MM; Schilsky RL; Kim ES; Wade JL
    Clin Cancer Res; 2021 May; 27(9):2408-2415. PubMed ID: 33563637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Significance of Eligibility Criteria Determined by the SPIRITS Trial in Patients with Advanced Gastric Cancer.
    Satake S; Arigami T; Matsushita D; Okubo K; Shimonosono M; Sasaki K; Tsuruda Y; Tanabe K; Mori S; Yanagita S; Uenosono Y; Nakajo A; Kurahara H; Ohtsuka T
    Oncology; 2023; 101(1):12-21. PubMed ID: 36198262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study.
    Brooks SE; Carter RL; Plaxe SC; Basen-Engquist KM; Rodriguez M; Kauderer J; Walker JL; Myers TK; Drake JG; Havrilesky LJ; Van Le L; Landrum LM; Brown CL
    Gynecol Oncol; 2015 Jul; 138(1):101-8. PubMed ID: 25937529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determinants of Treatment Eligibility in Veterans With Hepatitis C Viral Infection.
    Taylor J; Carr-Lopez S; Robinson A; Malmstrom R; Duncan K; Maniar A; Re ACD; Carmichael JM
    Clin Ther; 2017 Jan; 39(1):130-137. PubMed ID: 27989619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
    Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
    Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.
    Garcia S; Bisen A; Yan J; Xie XJ; Ramalingam S; Schiller JH; Johnson DH; Gerber DE
    J Thorac Oncol; 2017 Oct; 12(10):1489-1495. PubMed ID: 28802905
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
    Pan IW; Mallick R; Dhanda R; Nadler E
    Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization.
    Hordijk-Trion M; Lenzen M; Wijns W; de Jaegere P; Simoons ML; Scholte op Reimer WJ; Bertrand ME; Mercado N; Boersma E;
    Eur Heart J; 2006 Mar; 27(6):671-8. PubMed ID: 16423872
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility.
    Percival MM; Othus M; Mirahsani S; Gardner KM; Shaw C; Halpern AB; Becker PS; Hendrie PC; Sorror ML; Walter RB; Estey EH
    Haematologica; 2021 Aug; 106(8):2114-2120. PubMed ID: 32646891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015.
    Jin S; Pazdur R; Sridhara R
    J Clin Oncol; 2017 Nov; 35(33):3745-3752. PubMed ID: 28968168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Most children with cancer are not enrolled on a clinical trial in Canada: a population-based study.
    Pole JD; Barber R; Bergeron RÉ; Carret AS; Dix D; Kulkarni K; Martineau E; Randall A; Stammers D; Strahlendorf C; Strother DR; Truong TH; Sung L
    BMC Cancer; 2017 Jun; 17(1):402. PubMed ID: 28583094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
    Ho MY; Kennecke HF; Renouf DJ; Cheung WY; Lim HJ; Gill S
    Am J Clin Oncol; 2017 Dec; 40(6):552-554. PubMed ID: 26165420
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Who is eligible for randomized trials? A comparison between the exclusion criteria defined by the ISCHEMIA trial and 3102 real-world patients with stable coronary artery disease undergoing stent implantation in a single cardiology center.
    Wasilewski J; Poloński L; Lekston A; Osadnik T; Reguła R; Bujak K; Kurek A
    Trials; 2015 Sep; 16():411. PubMed ID: 26373291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.